Menarini Silicon Biosystems published the patent WO2026180447A1 for anti-LAYN antibodies.

Menarini Silicon Biosystems (MSB) is the only CLIA lab that offers circulating tumor cell (CTC) enumeration and phenotyping with CellSearch® as well as comprehensive genomic profiles of tumor cell-fee DNA and RNA (cfDNA/RNA) with MenariniSearch. The CellSearch® platform is the Gold Standard of CTC technology and offers a minimally invasive approach to follow your cancer patient’s therapeutic journey through standardized enumeration of circulating tumor cells and biomarker testing in solid tumors and multiple myeloma. MenariniSearch comprehensive genomic profiles detect a broader range of genetic alterations, to discover novel biomarkers and therapeutic targets that could enhance patient care. MenariniSearch tests use next-generation sequencing powered by artificial intelligence and are available for most cancer types. MSB’s tests are CLIA and CAP accredited LDTs that are reviewed by pathologists and can be performed on peripheral blood, cerebrospinal fluid, tissue, and bone marrow. Menarini Silicon Biosystems, based in Huntingdon Valley, PA, US, is a wholly-owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology, and diagnostics company headquartered in Florence, Italy, with 17,640 employees in 136 countries. Read our Netiquette here: www.siliconbiosystems.com/netiquette